Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 6, 2001
More information
Peak re-listed China's top 100 cement production capacity Daye peak won the "smart factory leader"
On July 11-12, the 2022 China Cement Industry Summit and TOP100 Award Ceremony organized by China Cement Network, an authoritative media of China's cement industry, was held in Hangzhou. Jianfeng Group once again ranked among the top 100 cement clinker production capacity in China.
2022
08-04
On the afternoon of July 12, the party Committee of the group company held a special meeting attended by party Committee members, senior and middle-level management backbones, heads of grass-roots party organizations and all party members of the group headquarters to learn and convey the spirit of the 15th party congress of the communist party of China in Zhejiang province.
2022
07-24
On the morning of July 1, more than 40 members of the group's party committee, party members of various branches of the group headquarters, and party members of subordinate enterprise branches went to the Shuanglong Hydropower Station, the Red Education Base of Jinhua City, to receive party spirit and revolutionary tradition education.
2022
07-14
Vocational skill level identification examination!
On June 16 and 18, the theoretical and practical examinations for the determination of professional skill level in the peak pharmaceutical sector were held successively in Jinxi pharmaceutical factory. The independent identification of vocational skill level includes three occupations (types of work): pharmaceutical preparation worker, chemical inspector and organic synthesis worker, basically covering the main posts in the pharmaceutical sector, with a total of 125 employees signing up for the identification.
2022
06-21
On June 16, the Jianfeng Pharmaceutical Quality Research and Development Party Branch and the Jinhua Vocational Skills Management Service Center Party Branch held a signing ceremony in Jinxi Factory to establish a party building alliance.
2022
06-21
Jinhua Mayor Xing Zhihong to Peak Research
On the afternoon of June 1, Jinhua Mayor Xing Zhihong, Wucheng District Party Committee Secretary Gao Feng, District Mayor Hu Yuxian, and heads of the Municipal Economic and Information Bureau, Development and Reform Bureau and other departments went to the group headquarters to discuss and exchange with the leaders of the group company to understand the development of the enterprise. Solicit opinions and suggestions from enterprises on government work. After understanding the current business situation of the peak, Xing Zhihong pointed out that focus, follow the right path, frontier, steady, is the peak to long-term prosperity of the magic weapon, must continue to adhere.
2022
06-13
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page